NO20030232L - Valsartansalter - Google Patents

Valsartansalter

Info

Publication number
NO20030232L
NO20030232L NO20030232A NO20030232A NO20030232L NO 20030232 L NO20030232 L NO 20030232L NO 20030232 A NO20030232 A NO 20030232A NO 20030232 A NO20030232 A NO 20030232A NO 20030232 L NO20030232 L NO 20030232L
Authority
NO
Norway
Prior art keywords
valsartansalter
Prior art date
Application number
NO20030232A
Other languages
English (en)
Other versions
NO20030232D0 (no
NO326504B1 (no
Inventor
Erwin Marti
Hans Rudolf Oswald
Peter Buehlmayer
Wolfgang Marterer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20030232(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20030232D0 publication Critical patent/NO20030232D0/no
Publication of NO20030232L publication Critical patent/NO20030232L/no
Publication of NO326504B1 publication Critical patent/NO326504B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20030232A 2000-07-19 2003-01-17 Valsartansalter, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk preparat inneholdende en slik forbindelse NO326504B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00115556 2000-07-19
PCT/EP2001/008253 WO2002006253A1 (en) 2000-07-19 2001-07-17 Valsartan salts

Publications (3)

Publication Number Publication Date
NO20030232D0 NO20030232D0 (no) 2003-01-17
NO20030232L true NO20030232L (no) 2003-01-17
NO326504B1 NO326504B1 (no) 2008-12-15

Family

ID=8169294

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030232A NO326504B1 (no) 2000-07-19 2003-01-17 Valsartansalter, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk preparat inneholdende en slik forbindelse

Country Status (30)

Country Link
US (5) US20030207930A1 (no)
EP (1) EP1313714B1 (no)
JP (1) JP4102664B2 (no)
KR (1) KR100529658B1 (no)
CN (2) CN1216873C (no)
AR (2) AR032758A1 (no)
AT (1) ATE406355T1 (no)
AU (2) AU8967201A (no)
BR (1) BR0112665A (no)
CA (1) CA2415962C (no)
CY (1) CY1108559T1 (no)
CZ (1) CZ303389B6 (no)
DE (1) DE60135560D1 (no)
DK (1) DK1313714T3 (no)
EC (1) ECSP034436A (no)
ES (1) ES2309090T3 (no)
HU (1) HU229280B1 (no)
IL (2) IL153882A0 (no)
MX (1) MXPA03000525A (no)
MY (2) MY152846A (no)
NO (1) NO326504B1 (no)
NZ (1) NZ523557A (no)
PE (1) PE20020613A1 (no)
PL (1) PL205715B1 (no)
PT (1) PT1313714E (no)
RU (1) RU2275363C2 (no)
SI (1) SI1313714T1 (no)
SK (1) SK287558B6 (no)
WO (1) WO2002006253A1 (no)
ZA (1) ZA200300285B (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0112665A (pt) 2000-07-19 2003-06-24 Novartis Ag Sais
PT1467728E (pt) * 2002-01-17 2007-11-14 Novartis Ag Composições farmacêuticas compreendendo valsartan e inibidores da nep
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
WO2003089417A1 (en) * 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
WO2003097099A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
ES2315510T3 (es) * 2002-06-13 2009-04-01 Novartis Ag Sales de calcio de estatinas derivadas del indol.
GB0222056D0 (en) * 2002-09-23 2002-10-30 Novartis Ag Process for the manufacture of organic compounds
EP1511739B1 (en) 2003-03-17 2008-04-30 Teva Pharmaceutical Industries Ltd. Polymorphs of valsartan
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
TR200503396T1 (tr) * 2003-03-31 2006-08-21 Hetero Drugs Limited Yeni, amorf bir formda valsartan.
US7378531B2 (en) 2003-04-21 2008-05-27 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) * 2004-07-06 2006-01-12 Novartis Ag Combination of organic compounds
EA015108B1 (ru) * 2004-12-24 2011-06-30 КРКА, д.д., НОВО МЕСТО Способ получения твердой фармацевтической композиции, содержащей валсартан
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) * 2005-02-14 2005-03-23 Novartis Ag Combination of organic compounds
EP1896433A4 (en) * 2005-05-25 2010-06-02 Ipca Lab Ltd NEW CRYSTALLINE FORMS OF (S) -N- (1-CARBOXY-2-METHYL-PROP-1-YL) -N-PENTANOYL-N- [2 '- (1H-TETRAZOL-5-YL) BI-PHENYL-4 ylmethyl] amine
FR2886642B1 (fr) * 2005-06-06 2008-05-30 Sanofi Aventis Sa Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
WO2007071750A1 (en) * 2005-12-22 2007-06-28 Enantia, S.L. Intermediates and processes for the preparation of valsartan
EP2043607A2 (en) * 2006-06-23 2009-04-08 Usv Limited Process for the preparation of micronized valsartan
WO2008018843A1 (en) * 2006-08-08 2008-02-14 Ulkar Kimya Sanayi Ve Ticaret As Process for producing useful salts form of biphenyl-tetrazole compounds
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
JP2010526126A (ja) * 2007-05-07 2010-07-29 シプラ・リミテッド バルサルタンの製造方法
EP1849777B1 (en) * 2007-06-07 2008-10-29 Inke, S.A. Process for obtaining a valsartan salt useful for obtaining valsartan
DK2209786T3 (da) * 2007-10-05 2013-06-03 Verastem Inc Pyrimidinsubstituerede purinderivater
CN101848700A (zh) 2007-11-06 2010-09-29 诺瓦提斯公司 基于血管紧张素受体拮抗剂/阻断剂(arb)和中性内肽酶(nep)抑制剂的超结构的双重作用的药物组合物
RU2488393C2 (ru) 2007-11-12 2013-07-27 Новартис Аг Жидкие композиции, включающие валсартан
EP2601180A1 (en) 2010-08-03 2013-06-12 Novartis AG Highly crystalline valsartan
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
MX340590B (es) * 2011-01-20 2016-07-13 Jiangsu Hanson Pharmaceutical Co Ltd Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
ES2699257T3 (es) 2013-02-28 2019-02-08 Dermira Inc Sales de glicopirrolato
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) * 2015-09-07 2017-03-16 Sun Pharmaceutical Industries Limited Solid forms of valsartan and sacubitril
CN105541741A (zh) * 2016-01-14 2016-05-04 青岛友诚高新技术有限公司 一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) * 2016-07-29 2016-12-21 陈欣怡 一种缬沙坦的新型固体形式
TWI648267B (zh) * 2016-09-02 2019-01-21 諾瑞特國際藥業股份有限公司 纈沙坦二鈉鹽新晶型
WO2018040065A1 (zh) * 2016-09-02 2018-03-08 诺瑞特国际药业股份有限公司 缬沙坦二钠盐的晶型
RU2019115782A (ru) * 2016-10-28 2020-11-30 Биокон Лимитед Аморфный тринатрий сакубитрил вальсартан и способ его получения
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
US20200276129A1 (en) 2017-10-13 2020-09-03 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Tablet containing valsartan and sacubitril
EP3498698A1 (en) 2017-12-15 2019-06-19 Mankind Pharma Ltd Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) * 2018-09-18 2018-11-13 中国药科大学 一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
US12365654B2 (en) 2019-12-02 2025-07-22 Harman Finochem Limited Process for the preparation of highly pure valsartan

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4499017A (en) * 1983-06-06 1985-02-12 Pfizer Inc. Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
JPH05105698A (ja) * 1991-06-13 1993-04-27 Takeda Chem Ind Ltd ホスホン酸誘導体、その製造法および用途
EP0750500A1 (en) 1994-03-17 1997-01-02 Ciba-Geigy Ag Treatment of diabetic nephropathy with valsartan
FR2725987B1 (fr) * 1994-10-19 1997-01-10 Sanofi Sa Procede pour la preparation d'un derive de tetrazole sous deux formes cristallines et nouvelle forme cristalline de ce derive
WO1996031234A1 (en) 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
BR9611007A (pt) * 1995-10-06 1999-07-13 Novartis Ag Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
IT1301759B1 (it) * 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
BR0112665A (pt) 2000-07-19 2003-06-24 Novartis Ag Sais

Also Published As

Publication number Publication date
AR069374A2 (es) 2010-01-20
RU2275363C2 (ru) 2006-04-27
IL153882A0 (en) 2003-07-31
PE20020613A1 (es) 2002-08-07
EP1313714A1 (en) 2003-05-28
US20030207930A1 (en) 2003-11-06
JP2004504307A (ja) 2004-02-12
DK1313714T3 (da) 2008-12-15
MY136446A (en) 2008-10-31
SK552003A3 (en) 2003-07-01
US9499499B2 (en) 2016-11-22
HUP0300731A3 (en) 2006-05-29
SI1313714T1 (sl) 2009-02-28
PL205715B1 (pl) 2010-05-31
ATE406355T1 (de) 2008-09-15
NZ523557A (en) 2004-12-24
CZ303389B6 (cs) 2012-08-29
ZA200300285B (en) 2004-03-25
HUP0300731A2 (hu) 2003-09-29
KR100529658B1 (ko) 2005-11-21
IL153882A (en) 2009-09-01
US20080293791A1 (en) 2008-11-27
SK287558B6 (sk) 2011-02-04
CN100413852C (zh) 2008-08-27
MXPA03000525A (es) 2003-05-14
AR032758A1 (es) 2003-11-26
CY1108559T1 (el) 2014-04-09
MY152846A (en) 2014-11-28
NO20030232D0 (no) 2003-01-17
AU8967201A (en) 2002-01-30
NO326504B1 (no) 2008-12-15
AU2001289672B2 (en) 2005-12-08
ES2309090T3 (es) 2008-12-16
PL360737A1 (en) 2004-09-20
JP4102664B2 (ja) 2008-06-18
EP1313714B1 (en) 2008-08-27
ECSP034436A (es) 2003-03-10
CA2415962C (en) 2010-07-06
CA2415962A1 (en) 2002-01-24
US20070149587A1 (en) 2007-06-28
CZ2003117A3 (cs) 2003-05-14
WO2002006253A1 (en) 2002-01-24
BR0112665A (pt) 2003-06-24
CN1443176A (zh) 2003-09-17
HK1055963A1 (en) 2004-01-30
PT1313714E (pt) 2008-11-03
DE60135560D1 (de) 2008-10-09
CN1680341A (zh) 2005-10-12
US20140073677A1 (en) 2014-03-13
KR20030015888A (ko) 2003-02-25
HU229280B1 (en) 2013-10-28
CN1216873C (zh) 2005-08-31
US20120329844A1 (en) 2012-12-27
US8278339B2 (en) 2012-10-02

Similar Documents

Publication Publication Date Title
ATE290000T1 (de) Muscarinagonisten
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
NO20030232D0 (no) Valsartansalter
ATA2932001A (de) Schneefräse
DE50108963D1 (de) Schlauchklemme
DE50106867D1 (de) Kugelgelenk
DE50108226D1 (de) Vordralldüsenträger
DE50102988D1 (de) Bodenwischer
DE50104056D1 (de) Gewichtsmanschette
DE50100710D1 (de) Wischblatt
ATE298751T1 (de) 7-oxopyridoryrimidine
DE50104651D1 (de) Fahrzeugfaltverdeck
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE10192638T1 (de) Bohrstangenladevorrichtung
DE50109748D1 (de) Hydrolager
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50100817D1 (de) Kugelgelenk
DE50011511D1 (de) Blowby-Heizung
AR028061A1 (es) 2-enamino-cetonitrilos fenil-substituidos
DE50112451D1 (de) Befestigunsvorrichtung
DE50007634D1 (de) Kardioplegieballonkatheter
ATE476423T1 (de) Benzoylpyridazine
DE10052925B4 (de) Schaukelbett
DE10195909T1 (de) Viehfüttervorrichtung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees